Cervical Cancer
Investigational Treatment Study
Researchers at Precigen are conducting a research study in individuals with recurrent or metastatic cervical cancer to evaluate an investigational drug.
Fast Facts
Recurrent or Metastatic Cervical Cancer
Ages 18+
Had Unsuccessful Treatment with Pembrolizumab
Conducted Nationwide
Study Background
Researchers at Precigen want to evaluate an investigational drug to treat cervical cancer.
For some types of cancer, including cervical cancer, treatment can include immunotherapy with a drug called pembrolizumab. However, sometimes this treatment doesn’t work. In this research study, we want to test the safety and effectiveness of an investigational drug for people who have had unsuccessful pembrolizumab treatment.
Eventually, the findings of this study might be useful for treating cervical and other types of cancer.
Study Background
Researchers at Precigen want to evaluate an investigational drug to treat cervical cancer.
For some types of cancer, including cervical cancer, treatment can include immunotherapy with a drug called pembrolizumab. However, sometimes this treatment doesn’t work. In this research study, we want to test the safety and effectiveness of an investigational drug for people who have had unsuccessful pembrolizumab treatment.
Eventually, the findings of this study might be useful for treating cervical and other types of cancer.
Additional Information
In this research study, we aim to evaluate the safety and effectiveness of an investigational drug, in combination with pembrolizumab, versus pembrolizumab alone, in treating recurrent or metastatic cervical cancer.
You may qualify for a study if you meet the following criteria.
Inclusion Criteria:
- Ages 18+
- Diagnosed with cervical cancer that is recurrent or metastatic (spreading)
- Treatment with pembrolizumab proved unsuccessful
- No other unstable medical conditions
- Life expectancy is greater than 11 weeks
- Not using supplemental oxygen
- If female, not pregnant or breastfeeding
- No other cancer in past year
- No diagnosis of immunodeficiency or have an active auto-immune disease that requires medication >10 mg daily
After completing screening, the study involves up to 9 visits over about 12 weeks. Study visits will take place at one of our sites in either Bethesda, MD, Seattle, WA, or Little Rock, AR. We can provide travel reimbursement to help you get to a site.
Once enrolled, participants will be randomly assigned to one of two cohorts.
- Cohort 1: Receives the investigational drug plus pembrolizumab.
- Cohort 2: Receives only pembrolizumab.
We will collect blood samples at each treatment visit, as well as radiographic images every 6 weeks. If you are assigned to Cohort 2, you will be offered the option to switch to Cohort 1 after at least one cycle of pembrolizumab.
There is no cost for you to participate in our research study. If needed, we can offer travel reimbursement for you to travel to one of our study sites.
